AdAlta Ltd (ASX:1AD) managing director Tim Oldham updates Proactive on the health care stock’s lead AD-214 i-body after it secured ethics approval to extend a Phase 1 study. Eight more fibrotic disease patients suffering interstitial lung disease or chronic kidney disease will join part B of the trial, which is examining AD-214’s safety in a standard of care context. Oldham says the extension is pivotal in AdAlta’s mission to extend its earlier Phase 1 findings, support partnering endeavours and reduce Phase 2’s overall time and cost.
AdAlta extends I-body trial following ethics approval
